Research programme: Huntington's disease vaccine - AFFiRiS
Latest Information Update: 18 Jan 2016
At a glance
- Originator AFFiRiS
- Class Peptide vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 18 Jan 2016 Preclinical trials in Huntington's disease in Austria (unspecified route)